Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.80 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.76 |
| ▸ | ECE1 | P42892 | 2/20 | 0.76 |
| ▸ | MUS81 | Q96NY9 | 2/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | MGAM | O43451 | 1/20 | 0.69 |
| ▸ | SI | P14410 | 1/20 | 0.69 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.65 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.65 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ALPL | P05186 | 1/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983736 | 0.90 | AR (0.80) | ARECE2ECE1MUS81NTRK1 | |
| SCHEMBL14983767 | 0.89 | AR (1.00) | ARECE2ECE1MUS81NTRK1 | |
| SCHEMBL1175104 | 0.88 | AR (0.82) | ARECE2ECE1MUS81GAA | |
| SCHEMBL1175103 | 0.88 | AR (0.82) | ARECE2ECE1MUS81GAA | |
| SCHEMBL29874298 | 0.88 | AR (0.82) | ARECE2ECE1MUS81GAA | |
| SCHEMBL12868822 | 0.88 | AR (0.82) | ARECE2ECE1MUS81GAA | |
| SCHEMBL16653952 | 0.86 | ECE2 (1.00) | ARECE2ECE1MUS81NTRK1 | |
| SCHEMBL16653949 | 0.86 | ECE2 (1.00) | ARECE2ECE1MUS81NTRK1 | |
| SCHEMBL29695489 | 0.86 | ECE2 (1.00) | ARECE2ECE1MUS81NTRK1 | |
| SCHEMBL4570235 | 0.86 | ECE2 (1.00) | ARECE2ECE1MUS81NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-04-09 | — | — | US | disclosed |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-10-08 | — | — | US | disclosed |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-10-08 | — | — | US | disclosed |
| US-8809386-B2 | Use of dynamin ring stabilizers | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2014-08-19 | — | — | US | disclosed |
| US-8809386-B2 | Use of dynamin ring stabilizers | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2014-08-19 | — | — | US | disclosed |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | CLINT1, CLTC, DNM1L | AR 3432/4885ECE2 1743/4885ECE1 869/4885 |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | CLINT1, CLTC, DNM1L | AR 3432/4885ECE2 1743/4885ECE1 869/4885 |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | DNM1L, DNM1, DNM2 | AR 4768/4885ECE2 1084/4885ECE1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.